ClinicalTrials.gg

Program

BI 765423

A development code.

In Boehringer Ingelheim's pipeline, IL-11 antibody. Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.

Furthest: phase 2, since Jun 17, 20253 company-led studies, 1 open or runningNext primary completion: Mar 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim31 open or runningphase 2since Jun 17, 2025Dec 13, 2022Mar 11, 2027phase 2 · NCT07036523
  • Named in Boehringer Ingelheim’s own pipeline as BI 765423, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2022First study: phase 1 study in HealthyFirst studyNCT05658107 · 64 enrolled · Belgium
  2. Jan 22, 2024Phase 1 study in HealthyNCT06232252 · 38 enrolled · Belgium
  3. Jun 17, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT07036523 · 81 enrolled · United States, Australia, Belgium and more

Ahead

  1. Mar 11, 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07036523

TargetBeta

“IL-11 antibody”the company's pipeline, read by Claude · source

Other programs on IL11

ProgramCompanyFurthest phaseStudies
Anti-IL-11 Monoclonal Antibody 9MW3811ruleMabwell (Shanghai) Biosciencephase 24

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07036523Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more2Active, not recruitingMar 11, 202781
NCT06232252Healthy · Belgium1CompletedApr 25, 202538
NCT05658107Healthy · Belgium1CompletedMar 19, 202464

How it is read

Names in the registry

  • “BI 765423”, 3 entries

Codes read as this program: BI765423.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.